MedTrace Logo

OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)

NCT05814757 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-07-10

No results posted yet for this study

Summary

To assess the efficacy and safety of OTX-DED for the short-term treatment of the symptoms of DED

Conditions

  • Dry Eye Syndromes
  • Eye Diseases

Interventions

DRUG

OTX-DED

0.3mg dexamethasone ophthalmic insert

DRUG

Controlled Insertion

Collagen Punctal Plug 0.2mm (Controlled Insertion)

DRUG

Collagen Punctal Plug

Collagen Punctal Plug 0.2mm (Full Insertion)

Sponsors & Collaborators

  • Ocular Therapeutix, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-11
Primary Completion
2024-05-22
Completion
2024-05-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05814757 on ClinicalTrials.gov